Login | SITEMAP | FAQS

Research & Scientists | Surgical Sciences | People | FBALTAZAR

 

Name: Fátima Baltazar

Office: G1.24

School Phone: +351 253 604 828

Email: fbaltazar@med.uminho.pt

 

 

 

Keywords: monocarboxylate transporters cancer metabolism cancer targeted therapy

About

Fátima Baltazar (Baltazar F) holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (U.K., 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima’s main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitroand in vivocancer models. Fátima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications (ongoing). She supervised 5 post-doc projects, 10 PhD thesis, 18 Master thesis and several under-graduated research projects. Fatima´s research has been acknowledged by several national and international awards and she has also gathered several national and international research funds. Additionally, she organized 27 post-graduation courses and meetings.

She is member of the Editorial Board of several international journals, and member of different national and international organizations, including ASPIC (Portuguese Association for Cancer Research), EACR(European Association for Cancer Research) and ISCaM(International Society of Cancer Metabolism).

Projects

Development of 3D culture systems for in vitro study of tumour pathophysiology (Leader) 

Role of Monocarboxylate transporters (MCTs) in cancer (Leader) 

Molecularly targeted therapies: mechanisms of resistance  

Selected Publications

Miranda-Gonçalves V, Granja S, Martinho O, Honavar M, Pojo M, Costa BM, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, Costa P, Reis RM, Baltazar F. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget, 2016; 7(29):46335-46353

Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Cordeiro M, Bebiano G, Costa P, Reis RM, Baltazar F. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic target. Neuro-Oncology, 2013;15(2):172-88.

Pértega-Gomes N, Felisbino S, Massie C, Vizcaíno JR, Coelho R, Sandi C, Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer L. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for Monocarboxylate Transporters as metabolic targets for therapy. J Pathol, 2015; 236(4):517-530

Morais-Santos F, Granja S, Miranda-Gonçalves V, Moreira A, Queirós S, Vilaça JL, Schmitt FC, Longatto-Filho A, Paredes J, Baltazar F, Pinheiro C. Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget, 2015; 6(22): 19177-19189.

Granja S, Marchiq I, Le Floch E, Souto-Moura C, Baltazar F, Pouyssegur J. Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status. Oncotarget, 2014; ahead of print.

Copyright © 2012-2016 ICVS. All rights reserved.